Dapagliflozin prescribing across the NHS.
Dapagliflozin is the biggest SGLT2 inhibitor in England, £130.0m at list price on 12.9m items in the 12 months to July 2026. What began as a diabetes drug now earns much of its growth from heart failure and kidney disease, and that indication spread is the story a commercial team needs to read carefully.
The NHS in England dispensed 12,946,163 prescription items of Dapagliflozin in the 12 months to July 2026, across primary care and hospitals.
Spending on Dapagliflozin over those 12 months was £130.0m at net ingredient cost, the list price of what was dispensed before any discounts.
Items were up 34.4% on the previous 12 months.
98% of Dapagliflozin volume moved through primary care and 2% through hospital pharmacies.
Dapagliflozin is the largest of 28 chemical substances in Other antidiabetic drugs (BNF 6.1.2.3), by items dispensed.
Among Integrated Care Boards, NHS West and North London ICB dispensed the highest volume of Dapagliflozin.
Source: NHS Business Services Authority open data (English Prescribing Data and SCMD), OGL v3.0. Items count prescriptions dispensed, not patients treated.
Diamond markers show events around this period: NICE decisions, safety alerts, supply notices, Drug Tariff moves and price concessions, new suppliers in dm+d and framework awards. Hover a marker for the date and type. The evidence behind each one, with the source quote and link, sits behind Apply.
| Month | Items | Spend (NIC) |
|---|---|---|
| July 2026 | 1,375,573 | £4.1m |
| June 2026 | 1,264,636 | £4.3m |
| May 2026 | 1,156,827 | £6.5m |
| April 2026 | 1,134,500 | £7.7m |
| March 2026 | 1,119,584 | £6.6m |
| February 2026 | 988,448 | £5.9m |
| January 2026 | 1,038,809 | £6.7m |
| December 2025 | 1,061,006 | £8.5m |
| November 2025 | 943,692 | £11.3m |
| October 2025 | 998,301 | £11.9m |
| September 2025 | 957,653 | £24.0m |
| August 2025 | 907,134 | £32.4m |
The same series as the chart, most recent month first. The full monthly history, as CSV, sits behind Apply.
46.2% of its class.
Dapagliflozin is the largest of 28 chemical substances in Other antidiabetic drugs (BNF 6.1.2.3), by items dispensed in July 2026. The full class league, who's gaining, and the month-by-month share movement sit behind Apply.
Average items by calendar month across the full history, indexed to the annual mean.
23 suppliers hold a live dapagliflozin listing, across 45 packs.
A A H Pharmaceuticals Ltd, Accord-UK Ltd, Alliance Healthcare (Distribution) Ltd, Amarox Ltd, AstraZeneca UK Ltd, Celix Pharma Ltd, CST Pharma Ltd, Dexcel-Pharma Ltd, Dr Reddy's Laboratories (UK) Ltd, Glenmark Pharmaceuticals Europe Ltd, Krka UK Ltd, Macleods Pharma UK Ltd, Milpharm Ltd, MSN Laboratories Europe Ltd, Rudipharm Ltd, Sandoz Ltd, Sun Pharmaceutical Industries Europe B.V., Teva UK Ltd, Thornton & Ross Ltd, Torrent Pharma (UK) Ltd, Viatris UK Healthcare Ltd, Wockhardt UK Ltd, Zydus Pharmaceuticals UK Ltd. In the last twelve months 0 packs were listed and 4 discontinued. Every pack, its GTIN and published list price, and each week's changes are in the full report.
A listing in the NHS Dictionary of Medicines and Devices means a product may be supplied. It says nothing about sales or market share, and the list price is the reimbursement price, not what any buyer pays. Contains information from dm+d 10.1.0, published by the NHS Business Services Authority under the Open Government Licence v3.0.
1,260,794 people in England had at least one dapagliflozin item prescribed in primary care in 2025/26, 9.1 items each. Source: NHSBSA Prescribing for Diabetes, England, official statistics, OGL v3.0. Identified patients only.
Dapagliflozin across all 36 ICBs.
Every Integrated Care Board in England, shaded by how much dapagliflozin its GPs dispense per head of population. Hover an ICB to name it. The ranked figures for all 36 ICBs, and the drill-down to practice level, are in the full report.
Darker shading marks where Dapagliflozin is dispensed most per head of population. Exact figures for every ICB, and the drill-down to practice level, are in the full report.
Zoomed out to the 7 NHS regions.
The same 12 months rolled up to NHS England's seven regions, ranked by intensity.
The teaser view.
Three rows each. The full 36-ICB view, every prescribing organisation, every strength and the hospital picture sit below the fold, behind Apply.
- 1 NHS West and North London ICB 925k
- 2 NHS North East and North Cumbria ICB 810k
- 3 NHS Central East ICB 737k
- – + 33 more. See the full 36-ICB table. See all →
- 1 NHS Derby and Derbyshire ICB +78.2%
- 2 NHS Leicester, Leicestershire and Rutland ICB +66.0%
- 3 NHS South Yorkshire ICB +54.7%
- – + 33 more. See every ICB, ranked. See all →
- 1 Dapagliflozin 10mg tablets 95%
- 2 Dapagliflozin 5mg tablets 4%
- 3 Forxiga 10mg tablets 1%
- – + 1 more. See every strength and pack. See all →
Split of items across NHSBSA primary care and SCMD hospital dispensing.
Prescribing by deprivation.
Items per 1,000 registered patients by deprivation decile (1 = most deprived), practice deprivation weighted by where each practice's patients live. Read the shape rather than the absolute level: the most and least deprived deciles cover far fewer practices, and age structure drives much of the gradient.
The devolved nations.
| Nation | Items · 12 months | Data to |
|---|---|---|
| England | 12.9m | July 2026 |
| Scotland | 706k | June 2026 |
| Northern Ireland | 292k | May 2026 |
| Wales | 911k | April 2026 |
Each nation publishes its own community prescribing data, with different coding and list rules, so read these per-nation rather than as an exact UK total. Sources: NHSBSA (England), Public Health Scotland, NHS Wales Shared Services Partnership, OpenDataNI. Used under the Open Government Licence v3.0.
What open data won't tell you about dapagliflozin.
That is also the honest limit of this page: open data does not record indication, so diabetes, heart failure and CKD prescribing are one undivided number here.
Asked and answered.
Is dapagliflozin prescribing rising or falling in the NHS?
Rising. England dispensed 12,946,163 items of Dapagliflozin in the 12 months to July 2026, up 34.4% on the previous 12 months. Items count prescriptions dispensed, not patients treated, so the change can reflect dose and duration shifts as well as patient numbers.
How much does the NHS spend on dapagliflozin?
£130.0m at net ingredient cost in the 12 months to July 2026. Net ingredient cost is the list price of the medicine before discounts and rebates; the NHS's final bill, especially for hospital medicines, is usually lower.
Where in England is dapagliflozin prescribed most?
By raw volume, NHS West and North London ICB dispensed the most dapagliflozin in the last 12 months. Raw volume favours the biggest populations; the map on this page shades every ICB by items per head to correct for that.
How up to date is this data?
This page runs to July 2026, the most recent NHSBSA release. Prescribing data publishes roughly six to eight weeks in arrears, and DoseTrend refreshes within 48 hours of each monthly release.
The full breakdown.
Every ICB, every prescribing organisation, every strength, the hospital view with what trusts paid and who holds each framework line, Signals with their sources, and the monthly briefing PDF. The rows below are placeholders; the real tables sit behind the application.
Related pages.
See the full molecule directory, or read about the data and pricing.
Track dapagliflozin like this, every month.
£1,500 a month per molecule. Apply and we'll pre-fill Dapagliflozin for you.